Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial.

Kevin L Winthrop,Alan W Skolnick,Adnan M Rafiq,Scott H Beegle,Julian Suszanski,Guenther Koehne,Ofra Barnett-Griness,Aida Bibliowicz,Reza Fathi,Patricia Anderson,Gilead Raday,Gina Eagle,Vered Katz Ben-Yair,Harold S Minkowitz,Mark L Levitt,Michael S Gordon

Open forum infectious diseases（2022）

引用 5|浏览5

暂无评分

摘要

In this proof-of-concept study, hypoxic, hospitalized patients receiving oral opaganib had a similar safety profile to placebo-treated patients, with preliminary evidence of benefit for opaganib as measured by supplementary oxygen requirement and earlier hospital discharge. These findings support further evaluation of opaganib in this population.

查看译文

关键词

SARS-CoV-2,hospitalization,sphingosine-kinase-2,supplemental oxygen

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要